跳至主要内容
临床试验/NCT04515446
NCT04515446进行中(未招募)不适用

Sequential Quantification of Viral Load in the Upper Respiratory Tract in Adult Patients Admitted for Influenza and Treated With Olsetamivir

Centre Hospitalier Universitaire de Nice2 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2020年2月4日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
18
试验地点
2
主要终点
The duration of influenza virus carriage in the upper airways in patients treated with olsetamivir will be observed

研究概览

简要总结

Seasonal influenza is a frequent disorder with high impact on morbidity and mortality and significant burden on healthcare-related cost. In France, the 2018-2019 flu epidemic has led to 13,100 all-cause death including 9,900 death directly related to the viral infection.

As cross-transmission of influenza is responsible for nosocomial outbreaks, preventing transmission of infectious agents in healthcare settings is a major issue. If vaccination of patients and healthcare givers remains cornerstone, control procedures are mandatory. Therefore patients admitted with influenza require isolation precautions including admission in a single room and protective measures. Based on experts advise, isolation is currently recommended for 5 to 8 days. Duration of isolation depends on immune status and antiviral therapy. However, during periods of epidemic, every hospital room is valuable and each ressource has to be tightly used. Risk of contamination is related to the presence of influenza in the upper airways. To the Promoteur 's knowledge, presence of influenza in the upper airways has not been studied in patients receiving oseltamivir. The question is : Do duration of isolation in patients admitted with flu decreas when they are treated with antiviral therapy. To answer this question The Promoteur would aim to determine influenza carriage in the upper airways in in-patients treated by olsetamivir.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients (≥18 years)
  • Positive testing for influenza (A or B)
  • Patients hospitalized and treated with olsetamivir
  • Signature of informed consent
  • Affiliation to healthcare insurance (France, Monaco)

排除标准

  • Refusal to participate
  • Admission to intensive care
  • Palliative care
  • Unable to give inform consent
  • Patients under legal protection

结局指标

主要结局

The duration of influenza virus carriage in the upper airways in patients treated with olsetamivir will be observed

时间窗: Within 8 days following patient's participation

次要结局

  • Duration of influenza virus carriage in the upper airways among patients treated with olsetamivir according to the viral strand (A or B) will be mesured(Within 8 days following patient's participation)
  • Duration of influenza virus carriage in the upper airways among patients treated with olsetamivir according to their vaccination status and comorbidities will be mesured and compared(Within 8 days following patient's participation)
  • Difference in the number of days in isolation in patients hospitalized and treated with olsetamivir will be evaluated(21 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验